Saturday, February 27, 2021

Market Analysts see Synthetic Biologics Inc. [SYN] gaining to $6. Time to buy?

Must read

Armstrong Flooring Inc (AFI) Hitting the mark

Armstrong Flooring Inc (AFI) ‎stock got some oxygen when the company publicly announced to sell its production facility and real state property of theSouth...

The Goodyear Tire & Rubber Company (GT): Keeping an Eye On The Long Term

The Goodyear Tire & Rubber Company (NASDAQ: GT) has acquired rival Cooper Tire & Rubber Company (NYSE: CTB) for $2.8 billion. The takeover will...

Synthetic Biologics Inc. [AMEX: SYN] closed the trading session at $0.83 on 02/22/21. The day’s price range saw the stock hit a low of $0.80, while the highest price level was $0.89. The company report on December 22, 2020 that Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

IRB Approval Signals Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients May Proceed as Planned; Enrollment Anticipated to Commence During Q1 2021.


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .

Sponsored


Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced it has received approval from the Institutional Review Board (IRB) at Washington University School of Medicine in St. Louis (Washington University), to commence the Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients. As a result, the Company expects to commence patient enrollment for the Phase 1b/2a clinical trial in the first quarter of 2021.

The stocks have a year to date performance of 117.36 percent and weekly performance of -16.33 percent. The stock has been moved at 65.74 percent over the last six months. The stock has performed -1.63 percent around the most recent 30 days and changed 137.86 percent over the most recent 3-months.

If compared to the average trading volume of 16.73M shares, SYN reached to a volume of 28789497 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Synthetic Biologics Inc. [SYN]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SYN shares is $1.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SYN stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

FBR & Co. have made an estimate for Synthetic Biologics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on January 06, 2017. While these analysts kept the previous recommendation, FBR Capital raised their target price from $10 to $9. The new note on the price target was released on May 06, 2016, representing the official price target for Synthetic Biologics Inc. stock. Previously, the target price had yet another raise to $10, while FBR Capital analysts kept a Outperform rating on SYN stock.

The Average True Range (ATR) for Synthetic Biologics Inc. is set at 0.13

SYN stock trade performance evaluation

Synthetic Biologics Inc. [SYN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -16.33. With this latest performance, SYN shares dropped by -1.63% in over the last four-week period, additionally plugging by 65.74% over the last 6 months – not to mention a rise of 68.83% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SYN stock in for the last two-week period is set at 48.03, with the RSI for the last a single of trading hit 41.13, and the three-weeks RSI is set at 51.55 for Synthetic Biologics Inc. [SYN]. The present Moving Average for the last 50 days of trading for this stock 0.6984, while it was recorded at 0.9235 for the last single week of trading, and 0.5070 for the last 200 days.

Synthetic Biologics Inc. [SYN]: An insightful look at the core fundamentals

Return on Total Capital for SYN is now -81.02, given the latest momentum, and Return on Invested Capital for the company is -69.24. Return on Equity for this stock declined to -69.99, with Return on Assets sitting at -64.60. When it comes to the capital structure of this company, Synthetic Biologics Inc. [SYN] has a Total Debt to Total Equity ratio set at 5.03. Additionally, SYN Total Debt to Total Capital is recorded at 4.79, with Total Debt to Total Assets ending up at 4.19.

Reflecting on the efficiency of the workforce at the company, Synthetic Biologics Inc. [SYN] managed to generate an average of -$1,391,182 per employee.Synthetic Biologics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.20 and a Current Ratio set at 2.20.

Earnings per share (EPS) analysis for Synthetic Biologics Inc. [SYN] stock

With the latest financial reports released by the company, Synthetic Biologics Inc. posted -0.19/share EPS, while the average EPS was predicted by analysts to be reported at -0.23/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 17.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SYN.

Synthetic Biologics Inc. [SYN]: Insider Ownership positions

There are presently around $1 million, or 2.40% of SYN stock, in the hands of institutional investors. The top three institutional holders of SYN stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 1,237,733, which is approximately 43.967% of the company’s market cap and around 0.37% of the total institutional ownership; FISHER ASSET MANAGEMENT, LLC, holding 125,698 shares of the stock with an approximate value of $0.1 million in SYN stocks shares; and BRIDGEWAY CAPITAL MANAGEMENT, LLC, currently with $91000.0 in SYN stock with ownership of nearly 0% of the company’s market capitalization.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Positions in Synthetic Biologics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 6 institutional holders increased their position in Synthetic Biologics Inc. [AMEX:SYN] by around 475,453 shares. Additionally, 7 investors decreased positions by around 102,208 shares, while 11 investors held positions by with 1,163,652 shares. The mentioned changes placed institutional holdings at 1,741,313 shares, according to the latest SEC report filing. SYN stock had 1 new institutional investments in for a total of 15,705 shares, while 4 institutional investors sold positions of 204 shares during the same period.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Armstrong Flooring Inc (AFI) Hitting the mark

Armstrong Flooring Inc (AFI) ‎stock got some oxygen when the company publicly announced to sell its production facility and real state property of theSouth...

The Goodyear Tire & Rubber Company (GT): Keeping an Eye On The Long Term

The Goodyear Tire & Rubber Company (NASDAQ: GT) has acquired rival Cooper Tire & Rubber Company (NYSE: CTB) for $2.8 billion. The takeover will...

OCUL stock: Ocular Therapeutix (OCUL) Is Better Than You Think

Ocular Therapeutix (OCUL) has performed well over the past year. OCUL has experienced a 248.76% gain in the last year, while its stock has...

Examining the Technicals of Levi Strauss & Co (NYSE: LEVI)

Levi Strauss & Co (NYSE: LEVI), one of the world's most famous denim brands, is recovering from the COVID-19 crisis. As a result of...

Philip Morris International’s Stock Is Driven By IQOS’s Increasing Growth: PM Stock

Shares of Philip Morris International (PM) reacted positively to the fourth quarter's earnings report. PM-related firms' stocks rose 8.77% for the week, with a...

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.